Medicus Pharma Ltd. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDCX research report →
Range $1 – $1
Price Chart
About the company
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
- CEO
- Raza Bokhari
- IPO
- 2024
- Employees
- 16
- HQ
- West Conshohocken, PA, CA
Get TickerSpark's AI analysis on MDCX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.06M
- P/E
- -0.10
- Fwd P/E
- 1.72
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -7.05
- EV/EBITDA
- -0.37
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 17867.26%
- ROIC
- -269.16%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-18,351,132
- Net Income
- $-25,366,424-127.4%
- EPS
- $-1.96-184.1%
- OCF Growth
- -122.3%
- FCF Growth
- -122.3%
- 52W High
- $2.78
- 52W Low
- $0.14
- 50D MA
- $0.23
- 200D MA
- $0.60
- Beta
- -0.61
- RSI (14)
- 37
- Avg Volume
- 4.37M
No earnings-call transcripts are available for MDCX yet.
- Free Float
- 73.4%
- Shares Outstanding
- 63.18M
- Float Shares
- 46.35M
of shares held by institutions
20 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Interchange Capital Partners, LLC | 1.59M | ▼ 75.00K |
| Jane Street Group, LLC | 333.67K | ▲ 333.67K |
| Xtx Topco Ltd | 243.36K | ▲ 243.36K |
| Sterling Investment Advisors, Ltd. | 100.00K | ▲ 100.00K |
| Commonwealth Equity Services, LLC | 52.64K | ▲ 4.50K |
| May Hill Capital, LLC | 50.62K | 0 |
| Susquehanna International Group, Llp | 31.46K | ▲ 31.46K |
| Stifel Financial Corp | 30.00K | ▲ 30.00K |
| Bryn Mawr Trust Co | 25.62K | ▼ 25.62K |
| Jpmorgan Chase & Co | 25.62K | ▲ 25.62K |
| Citadel Advisors LLC | 25.10K | ▲ 7.28K |
| Smithfield Trust Co | 24.61K | ▲ 13.13K |
Held by 1 ETFs
Biggest fund positions in MDCX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 4, 26 | Smith Andrew Alasdair | other | 735,294 |
| Sep 4, 26 | Smith Andrew Alasdair | other | 125,000 |
| Sep 4, 26 | Mehmud Faisal | other | 1,470,588 |
| Sep 4, 26 | Mehmud Faisal | other | 250,000 |
| Sep 4, 26 | Brennan Edward J. | other | 588,235 |
| Sep 4, 26 | Brennan Edward J. | other | 100,000 |
| Sep 4, 26 | Bonner Carolyn F. | other | 1,470,588 |
| Sep 4, 26 | Bonner Carolyn F. | other | 250,000 |
| Sep 4, 26 | Bokhari Raza | other | 2,941,176 |
| Sep 4, 26 | Bokhari Raza | other | 500,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MDCX coverage
Recent articles, reports, and earnings notes.
No research on MDCX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MDCX report →Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
proactiveinvestors.com · Sep 29
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
globenewswire.com · Sep 29
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
proactiveinvestors.com · Sep 21
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
globenewswire.com · Sep 21
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
proactiveinvestors.com · Sep 12
Wall Street sets positive tone as investors digest hotter inflation data
proactiveinvestors.com · Sep 11
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
proactiveinvestors.com · Sep 10
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
globenewswire.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.